Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) saw a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 60,000 shares, a growth of 20.2% from the March 15th total of 49,900 shares. Approximately 0.7% of the shares of the company are short sold. Based on […]
Gain Therapeutics (NASDAQ:GANX – Get Rating) had its price target boosted by Chardan Capital from $4.00 to $5.75 in a research report released on Monday, The Fly reports. Gain Therapeutics Stock Up 3.0 % GANX opened at $4.82 on Monday. The company has a debt-to-equity ratio of 0.03, a current ratio of 5.11 and a […]
Gain Therapeutics (NASDAQ:GANX – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Wednesday, Zacks.com reports. The firm presently has a $2.75 target price on the stock. Zacks Investment Research‘s price target indicates a potential upside of 3.77% from the stock’s previous […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) CEO Eric I. Richman acquired 4,000 shares of the business’s stock in a transaction on Thursday, May 19th. The shares were purchased at an average cost of $2.71 per share, for a total transaction of $10,840.00. Following the completion of the acquisition, the chief executive officer now directly […]
Gain Therapeutics, Inc. (NASDAQ:GANX – Get Rating) was the target of a large decline in short interest during the month of March. As of March 15th, there was short interest totalling 30,800 shares, a decline of 17.9% from the February 28th total of 37,500 shares. Approximately 0.4% of the shares of the company are sold […]